Search Results - Jim Sang

  • Showing 1 - 14 results of 14
Refine Results
  1. 1
    The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer

    The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer by Suqin He, Donald L. Smith, Manuel Sequeira, Jim Sang, Richard C. Bates, David A. Proia

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes

    Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes by Julie C. Friedland, Donald L. Smith, Jim Sang, Jaime Acquaviva, Suqin He, Chaohua Zhang, David A. Proia

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    mTOR Inhibition Potentiates HSP90 Inhibitor Activity via Cessation of HSP Synthesis

    mTOR Inhibition Potentiates HSP90 Inhibitor Activity via Cessation of HSP Synthesis by Jaime Acquaviva, Suqin He, Jim Sang, Donald L. Smith, Manuel Sequeira, Chaohua Zhang, Richard C. Bates, David A. Proia

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib

    Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib by Jaime Acquaviva, Donald L. Smith, Jim Sang, Julie C. Friedland, Suqin He, Manuel Sequeira, Chaohua Zhang, Yumiko Wada, David A. Proia

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib

    Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib by Jaime Acquaviva, Donald L. Smith, John-Paul Jimenez, Chaohua Zhang, Manuel Sequeira, Suqin He, Jim Sang, Richard C. Bates, David A. Proia

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression

    Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression by Suqin He, Chaohua Zhang, Ayesha A. Shafi, Manuel Sequeira, Jaime Acquaviva, Julie C. Friedland, Jim Sang, Donald L. Smith, Nancy L. Weigel, Yumiko Wada, David A. Proia

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling

    Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling by David A. Proia, Kevin P. Foley, Tim Korbut, Jim Sang, Don Smith, Richard C. Bates, Yuan Liu, Alex Rosenberg, Dan Zhou, Keizo Koya, James Barsoum, Ronald K. Blackman

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

    Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models by David A. Proia, Jim Sang, Suqin He, Donald L. Smith, Manuel Sequeira, Chaohua Zhang, Yuan Liu, Shuxia Ye, Dan Zhou, Ronald K. Blackman, Kevin P. Foley, Keizo Koya, Yumiko Wada

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism

    FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism by Jaime Acquaviva, Suqin He, Chaohua Zhang, John-Paul Jimenez, Masazumi Nagai, Jim Sang, Manuel Sequeira, Donald L. Smith, Luisa Shin Ogawa, Takayo Inoue, Noriaki Tatsuta, Margaret A. Knowles, Richard C. Bates, David A. Proia

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

    Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy by Weiwen Ying, Zhenjian Du, Lijun Sun, Kevin P. Foley, David A. Proia, Ronald K. Blackman, Dan Zhou, Takayo Inoue, Noriaki Tatsuta, Jim Sang, Shuxia Ye, Jamie Acquaviva, Luisa Shin Ogawa, Yumiko Wada, James Barsoum, Keizo Koya

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

    Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer by David A. Proia, Chaohua Zhang, Manuel Sequeira, John-Paul Jimenez, Suqin He, Neil L. Spector, Geoffrey I. Shapiro, Sara M. Tolaney, Masazumi Nagai, Jaime Acquaviva, Donald L. Smith, Jim Sang, Richard C. Bates, Iman El‐Hariry

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer

    Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer by Takeshi Shimamura, Samanthi A. Perera, Kevin P. Foley, Jim Sang, Scott J. Rodig, Takayo Inoue, Liang Chen, Danan Li, Julián Carretero, Yuchen Li, Papiya Sinha, Christopher D. Carey, Christa L. Borgman, John-Paul Jimenez, Matthew Meyerson, Weiwen Ying, James Barsoum, Kwok‐Kin Wong, Geoffrey I. Shapiro

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

    Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer by Jim Sang, Jaime Acquaviva, Julie C. Friedland, Donald L. Smith, Manuel Sequeira, Chaohua Zhang, Qin Jiang, Liquan Xue, Christine M. Lovly, John-Paul Jimenez, Alice T. Shaw, Robert C. Doebele, Suqin He, Richard C. Bates, D. Ross Camidge, Stephan W. Morris, Iman El‐Hariry, David A. Proia

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90

    Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 by Jens Sydor, Emmanuel Normant, Christine Pien, James R. Porter, Jie Ge, Louis Grenier, Roger H. Pak, Janid A. Ali, Marlene S. Dembski, Jebecka Hudak, Jon S. Patterson, Courtney Penders, Melissa Pink, Margaret Read, Jim Sang, Caroline Woodward, Yilong Zhang, David Grayzel, James R. Wright, John Barrett, Vito J. Palombella, Julian Adams, Jeffrey K. Tong

    Published 2006
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: